The firms originally inked the agreement in 2015 and have now extended it until 2025.
Universities and research institutes are making CRISPR/Cas9 more accessible than ever through new and existing core facilities.
Sales for the firm's life science segment jumped 25 percent year over year to €3.36 billion from €2.68 billion.
After falling for three years in a row, mergers and acquisitions in the omics space rose sharply in 2015, driven by a few billion-dollar-plus deals.
The deal creates a science sector giant able to "cover every step of the biotech production chain."
The firm expects its acquisition by Merck KGaA to be completed this month.
Based on Olink's proximity ligation technology, Duolink allows for detection of low-abundance proteins with higher specificity than conventional immunoassays.
Sigma-Aldrich will participate in the university's Catalyst Program, which is designed to support translation of early biomedical discoveries into commercial products.
Sigma-Aldrich is selling the business in order to gain approval from the EC for its $17 billion acquisition by Merck KGaA announced a year ago.
The arrayed lentiviral CRISPR/Cas9 guide RNA libraries provide the tools to knock out every known human or mouse protein-coding gene.
Thermo Fisher Scientific says it will no longer sell machines in China's Xinjiang region, according to the Wall Street Journal.
New Scientist reports that 20 percent of human and yeast proteins are uncharacterized.
The University of Zurich's Ruedi Aebersold and his colleagues analyzed a dozen HeLa cell lines to find differences in gene expression, protein levels, and more.
In Nature this week: protein-coding variants associated with body-fat distribution, and more.